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Soluble TREM2 ameliorates pathological
phenotypes by modulating microglial functions
in an Alzheimer’s disease model
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Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial surface receptor
genetically linked to the risk for Alzheimer’s disease (AD). A proteolytic product, soluble
TREM2 (sTREM2), is abundant in the cerebrospinal fluid and its levels positively correlate
with neuronal injury markers. To gain insights into the pathological roles of sTREM2,
we studied sTREM2 in the brain of 5xFAD mice, a model of AD, by direct stereotaxic injection
of recombinant sTREM2 protein or by adeno-associated virus (AAV)-mediated expression.
We found that sTREM2 reduces amyloid plaque load and rescues functional deficits of spatial
memory and long-term potentiation. Importantly, sTREM2 enhances microglial proliferation,
migration, clustering in the vicinity of amyloid plaques and the uptake and degradation of
Aβ. Depletion of microglia abolishes the neuroprotective effects of sTREM2. Our study
demonstrates a protective role of sTREM2 against amyloid pathology and related toxicity
and suggests that increasing sTREM2 can be explored for AD therapy.
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A lzheimer’s disease (AD) is a progressive neurodegenera-tive disorder and the most prominent cause of dementiain the elderly population. The histopathological hallmarks
of AD include the parenchymal deposition of amyloid-β (Aβ)
plaques, the formation of tau neurofibrillary tangles, and
neuroinflammation1,2. With the accumulation of these lesions in
the brain, AD patients ultimately suffer from synaptic loss, neu-
ronal death, and cognitive decline3. Although the pathogenic
events for AD are likely multifactorial, genetic, pathological, and
functional studies suggest that the disequilibrium between Aβ
production and clearance is a contributing and perhaps a driving
event leading to AD4. At present, enhancing the clearance of Aβ
remains an attractive therapeutic or preventive strategy for AD5.
Microglia are effective phagocytes in the central nervous system
(CNS) for the uptake and proteolytic clearance of both soluble
and fibrillary forms of Aβ6. Early studies have found that
microglial cells are clustered around amyloid plaques in the brain
of AD patients7,8 and AD mouse models9. Recently, plaque-
associated microglia have been shown to constitute a protective
barrier that compacts amyloid fibrils and reduces their
toxicity10,11. The roles of microglia in AD have been further
highlighted by recent genetic studies showing rare coding variants
in several genes highly expressed in microglia as risk factors
for late-onset AD12–19. Among them, a loss-of-function R47H
mutation in the triggering receptor expressed on myeloid cells 2
(TREM2) constitutes one of the strongest single-allele genetic risk
factors for AD13,15,16.
TREM2 is a type I transmembrane innate immune receptor
predominantly expressed by microglia within the CNS20,21.
The ectodomain of TREM2 has been reported to bind anionic
and zwitterionic lipids22, apolipoproteins (including apoE, apoJ,
and apoA) and lipoprotein particles23–25, and oligomeric Aβ
as reported recently26,27. In the disease context, TREM2 plays
important roles in microglial phagocytosis of apoptotic neurons,
damaged myelin, and amyloid plaques21,28. TREM2 has also been
shown to be essential for synaptic pruning in early develop-
ment29. Furthermore, TREM2 regulates microglial biosynthetic
metabolism30, proliferation31, survival31, cytokine release32, and
their accumulation around plaques11. The impact of TREM2 on
plaque accumulation was examined in Trem2-deficient AD
mouse models, but the results were conflicting22,33. Interestingly,
a later study suggested disease progression-dependent effects
of TREM2 on amyloid pathology by demonstrating that Trem2
deficiency ameliorates amyloid pathology early, but exacerbates
it late in the disease process34.
TREM2 undergoes regulated proteolytic cleavage by ADAM10
and ADAM17 at H157–S158 peptide bond, resulting in the lib-
eration of soluble TREM2 (sTREM2)35–37. sTREM2 is abun-
dantly detected in human cerebrospinal fluid (CSF) and its levels
are elevated in the CSF of patients with sporadic AD38–41.
Interestingly, the levels of sTREM2 change dynamically during
the progression of AD, peaking at the early symptomatic stages of
the disease38,40. Importantly, the CSF concentrations of sTREM2
correlate with neuronal injury markers, including the CSF
levels of total tau and phospho-tau; thus, they may serve as an
immunomodulatory biomarker for neurodegeneration. Remark-
ably, sTREM2 was found to co-localize with neurons and plaques
in vivo42, with functions remaining to be determined. We have
recently reported that sTREM2 exerts functional roles in micro-
glia by promoting inflammatory responses and shielding them
from apoptosis43. However, whether sTREM2 also has protective
effects against amyloid pathology and the related synaptic toxicity
remains to be defined. In this study, we explored the effects of
sTREM2 on pathological phenotypes in 5×FAD mouse model by
direct stereotaxic injection of recombinant sTREM2 protein or
by an adenovirus-associated virus (AAV)-mediated expression
strategy. We found that sTREM2 reduces amyloid-β (Aβ)
pathology and improves cognitive and synaptic functions by
modulating microglial activity in 5×FAD mouse model, thus
providing a rationale that sTREM2 can be explored for AD
therapy.
Results
sTREM2 reduces plaque load and the associated toxicity. We
had previously developed a mammalian expression and pur-
ification system for recombinant sTREM2 protein (Supplemen-
tary Fig. 1a)43. To assess the impact of sTREM2 on AD-related
pathology, we injected a recombinant sTREM2 protein into the
right hippocampus of 5×FAD mice, with phosphate-buffered
saline (PBS) injected into the left hippocampus as a vehicle
control (Fig. 1a). Twenty-four hours after stereotaxic injection of
sTREM2, immunofluorescence staining with human TREM2
antibody showed a sTREM2 distribution pattern that is diffused
but limited to the right hippocampus (Supplementary Fig. 1b).
However, the sTREM2 signal decayed thereafter and was barely
detectable on day 3 and 7 after injection. Seven days after delivery
to the hippocampus of 5×FAD mice, sTREM2 dramatically
reduced the amyloid plaque load in the ipsilateral hippocampus
(Fig. 1b, c). Of note, the number of large plaques (>40 μm in
diameter) was markedly reduced by sTREM2 (P < 0.0001, paired
Student’s t test) (Fig. 1d).
In addition to the amount of Aβ accumulation, the degree of
plaque compaction plays a crucial role in determining the
neurotoxicity of the plaque. It has been suggested that microglia
clustered around the amyloid plaque constitute a barrier which
impacts plaque composition and toxicity10. To gain insight into
the effects of sTREM2 on microglial barrier function, we
quantified the number of microglia in the vicinity of an amyloid
plaque and found a significant increase upon sTREM2 admin-
istration (Fig. 1e, f). Consistent with its protective effects on
plaque deposition, sTREM2 significantly reduced the total area of
dystrophic neurites, as detected by immunostaining with an
antibody against Lamp1 (Fig. 1g, h). However, no significant
differences were observed between vehicle and sTREM2 treat-
ment when calculating the amount of dystrophic neurites per
plaque (Fig. 1i). Thus, distinct from the full-length TREM2,
sTREM2 is unlikely involved in compacting amyloid fibrils to
reduce their toxicity11. Collectively, these data reveal that
sTREM2 protein reduces amyloid plaque deposition and
enhances the clustering of microglia in the vicinity of the
plaque, thereby reducing plaque load and the plaque-associated
neurotoxicity.
sTREM2 promotes microglial proliferation and migration.
Proliferation and activation of microglia around the sites of amyloid
plaque deposition is a prominent feature of AD44. The ionized
calcium-binding adapter molecule 1 (Iba1) is widely employed as an
immunohistochemical marker for both ramified and activated
microglia, and its expression is increased upon microglial
activation45,46. We found that the expression of Iba1 in the hippo-
campus of 5×FAD mice was significantly increased at the protein
level, and a trend toward increased mRNA level upon sTREM2
administration (Fig. 2a–c). However, no significant differences
were detected for the astrocytic marker GFAP. Staining of brain
sections further revealed that sTREM2 administration led to a sig-
nificantly higher number of proliferating microglia (Iba1+/Ki67+)
and the total number of microglia (Iba1+) in the hippocampus
(Fig. 2d–f). Interestingly, the increased Iba1 staining induced by
sTREM2 on day 1 was sustained throughout day 7, even though
sTREM2 was barely detectable on day 3 and 7 after injection
(Supplementary Fig. 1b). In addition to Iba1, the expression levels of
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pro-inflammatory cytokines, including IL-1β and TNF, were sig-
nificantly increased in the presence of sTREM2 (Supplementary
Fig. 2a), consistent with our previous report that sTREM2 promotes
microglial activation43. Importantly, both the pro-inflammatory
cytokine IL-1β and the immune-activating molecule lipopoly-
saccharide enhanced the production of sTREM2 in primary
microglia, as measured by enzyme-linked immunosorbent assay
(ELISA); while the anti-inflammatory cytokine IL-10 had a minimal
effect (Supplementary Fig. 2b). Therefore, sTREM2 and the pro-
inflammatory cytokines appear to form a positive feedback loop,
resulting in sustained microglial activation.
Since sTREM2 increases the number of plaque-associated
microglia, we further tested a hypothesis that sTREM2
might act as a chemoattractant to promote microglial
migration. Primary microglia isolated from wild-type (WT)
mice were subjected to the transwell migration assay in the
presence or absence of sTREM2. Interestingly, treatment with
native but not heat-inactivated sTREM2 led to increased
migration of microglia, as compared with the vehicle control
(Fig. 2g, h). Our data hence suggest that sTREM2 not only
enhances microgliosis in 5×FAD mice, but also acts as a
chemoattractant for microglia.
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sTREM2 promotes microglial phagocytosis and clearance of
Aβ. Microglia clustering in the vicinity of plaques is interpreted
as an attempt to clear the pathological deposits of Aβ through
phagocytosis and degradation. Indeed, quantitative assessment of
the area of colocalization of Aβ with CD68, a phagocytic marker
for microglia in the brain, revealed a significant increase in
sTREM2-injected 5×FAD mice (Fig. 3a, b), suggesting that sTREM2
likely promotes phagocytic Aβ uptake by microglia. To further test
this in vivo, we administered intraperitoneally methoxy-X04 3 h
prior to microglial isolation and analyzed the proportion of
methoxy-X04-positive microglial cells by flow cytometry. Com-
paring PBS-injected WT mice and 5×FAD mice treated with native
or heat-inactivated sTREM2 revealed a significant increase in the
number of CD11b+ CD45low resident microglia in sTREM2-
administered 5×FAD mice, while no significant change was
observed for the number of CD11b+CD45high peripheral macro-
phage (Fig. 3c, d). Therefore, the increased number of Iba1-positive
cells upon sTREM2 treatment is likely contributed by resident
microglia rather than infiltrating macrophages. A significant
increase in the proportion of methoxy-X04-positive microglial
cells was observed for 5×FAD mice injected with native sTREM2
(Fig. 3e, f), further demonstrating that sTREM2 enhances microglial
phagocytosis of Aβ in vivo.
We further examined the effects of sTREM2 on Aβ uptake and/
or degradation in cultured microglial cells. Primary postnatal
microglia isolated from WT mice were incubated with fluores-
cently FAM-labeled Aβ42 (FAM-Aβ42). We found an increase
in FAM-Aβ42 uptake upon sTREM2 stimulation (Fig. 3g, h).
However, the effect was diminished in the presence of a
phagocytosis inhibitor cytochalasin D. To further investigate
the role of sTREM2 in microglial Aβ endocytic trafficking,
we incubated microglial cells with Aβ, together with vehicle
control or sTREM2 in the presence or absence of lysosomal
enzyme inhibitors (Pepstatin A, Leupeptin, and E-64d) or
chloroquine. Cell-associated Aβ levels were significantly increased
by sTREM2 in the presence of lysosomal inhibitors (Fig. 3i and
Supplementary Fig. 3a). When lysosomal degradation of Aβ was
calculated by subtracting the cell-associated Aβ in the absence
of inhibitors from that in the presence of inhibitors, we found
that sTREM2 significantly enhanced Aβ lysosomal degradation,
as compared with vehicle control (Fig. 3j and Supplementary
Fig. 3b).
Since the steady-state levels of brain Aβ represent a dynamic
equilibrium between its rate of clearance and production from
the amyloid precursor protein (APP), we further explored the
molecular mechanism by which sTREM2 reduces Aβ levels. We
performed a series of experiments to evaluate whether sTREM2
induces changes in the levels of APP, its cleavage products, or
Aβ-degrading enzymes in sTREM2-injected 5×FAD mice. No
significant changes in the levels of full-length APP, α-CTF, or
β-CTF were detected upon sTREM2 injection in 5×FAD mice
(Supplementary Fig. 3c, d). Quantitative real-time polymerase
chain reaction (PCR) of the transcript levels of Aβ-degrading
enzymes, including insulin-degrading enzyme (IDE), neprilysin
(NEP), endothelin-converting enzyme 1 (ECE1), matrix metallo-
proteinase 2 (MMP2), and matrix metalloproteinase 9 (MMP9),
did not detect any significant alterations in response to sTREM2
treatment (Supplementary Fig. 3e). Taken together, we provide
both in vivo and in vitro evidence that sTREM2 promotes
microglial phagocytosis and clearance of Aβ, which may account
for sTREM2-mediated reduction of Aβ deposition in the brain
of 5×FAD mice.
Microglia are essential for the protective effects of sTREM2.
Both our current and previous studies pinpoint a critical role of
sTREM2 in modulating microglial function43. To determine
whether microglia mediate the protective effects of sTREM2 on
amyloid pathology, we employed the CSF1R inhibitor PLX3397
to deplete microglia from 5×FAD mice47,48. Following 14 days
of PLX3397 treatment, microglial number as assessed by
Iba1 staining was substantially reduced, with efficiency compar-
able with the previous work in 5×FAD mice (Supplementary
Fig. 4a, b)48. Consistent with previous reports that microglial
elimination in 5×FAD mice prevents neuronal loss48, increased
levels of synaptic markers (including NR2A, NR1, GluR1, and
vGluT1) were observed in PLX3397 administered to 5×FAD mice
(Supplementary Fig. 4c, d). However, no significant changes in
the levels of full-length APP, α-CTF, or β-CTF were detected
upon PLX3397 treatment. To determine if microglia are
responsible for sTREM2-mediated plaque reduction, we depleted
microglia with 14 days of PLX3397 treatment, followed by
administering sTREM2 to the hippocampus of 5×FAD mice
(Fig. 4a). In contrast to the control without PLX3397 treatment,
the plaque load was no longer reduced by sTREM2 in 5×FAD
mice treated with PLX3397, suggesting an indispensable role
of microglia in sTREM2-mediated plaque reduction (Fig. 4b, c).
Next, we studied the impact of sTREM2 administration on
hippocampal synaptic plasticity by inducing long-term poten-
tiation (LTP) in the Schaffer collateral (SC) pathway with high-
frequency stimulation. Intriguingly, the LTP impairment of
5×FAD mice was ameliorated when acute hippocampal slices
obtained from 5×FAD mice were pre-incubated with sTREM2
protein as compared with the vehicle control (Fig. 4d, f). More
interestingly, such effects were diminished in microglia-
depleted 5×FAD mice (Fig. 4e, f), suggesting that microglia
mediate the protective functions of sTREM2 in synaptic
plasticity. In contrast to the 5×FAD mice, sTREM2 had
Fig. 1 sTREM2 reduces amyloid plaque deposition and increases the number of plaque-associated microglia. a The 5×FAD mice at 7-month-old age were
injected with vehicle (PBS) in the left hemisphere and 6 μg of sTREM2 protein in the right hemisphere. b Coronal sections of vehicle- or sTREM2-injected
5×FAD mice were stained with DAPI (blue) for nuclei and MOAB-2 (green) for Aβ. Representative z-stack images of the hippocampus regions are shown.
Original magnification ×20; scale bar, 100 μm. c Quantitation of amyloid plaque deposition in b (n= 6 mice, 28 fields of each group for analysis, paired
Student’s t test). d Quantitation of the number of plaques with different sizes in b (n= 6 mice, 28 fields of each group for analysis, paired Student’s t test).
e Coronal sections from sTREM2-injected 5×FAD mice were stained with DAPI (blue) for nuclei, MOAB-2 (green) for Aβ, and Iba1 (red) for microglia.
Representative z-stack images of the hippocampus regions are shown. Scale bar, 25 μm. f Quantitation of the number of plaque-associated microglia in
e (n= 4 mice, 58 plaques of vehicle and 41 plaques of sTREM2 for analysis, paired Student’s t test). Plaques with 50 μm in diameter were selected for
analysis. g Coronal sections from sTREM2-injected 5×FAD mice were stained with DAPI (blue) for nuclei, MOAB-2 (green) for Aβ, Iba1 (red) for microglia,
and Lamp1 (white) for dystrophic neurites. Representative z-stack images of the hippocampus regions are shown. Original magnification ×20; scale
bar, 100 μm. Zoom-in images on the right with a scale bar equal to 25 μm. h Quantitation of the total area of Lamp1-positive dystrophic neurites in
g (n= 6 mice, 20 fields of each group for analysis, paired Student’s t test). i Quantitation of the area of Lamp1-positive dystrophic neurites within
each plaque in g (n= 6 mice, 40 plaques of vehicle and 41 plaques of sTREM2 for analysis, paired Student’s t test). All data are presented as mean ± SEM.
*p < 0.05; **p < 0.01; ****p < 0.0001; ns, not significant
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minimal effects on the LTP in either microglia-intact or
microglia-eliminated WT mice (Supplementary Fig. 4e–g). To
better understand synaptic alterations upon sTREM2 adminis-
tration, we examined the levels of various proteins involved in
synaptic plasticity and function. The levels of postsynaptic
glutamate (AMPAR) receptor subunits (GluR1 and GluR2)
and the presynaptic vesicular glutamate transporter 1 (vGluT1)
were significantly increased upon sTREM2 treatment in the
hippocampus (Fig. 4g, h). However, sTREM2 could no longer
increase the levels of these proteins in the absence of microglia
(Fig. 4i, j).
Recently, sTREM2 was found to co-localize with neurons
in vivo42. To further investigate whether neurons directly respond
to sTREM2, primary neuronal cultures at DIV 12–14 were
incubated with sTREM2 and subjected to whole-cell patch-clamp
experiments to record miniature excitatory postsynaptic currents
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Fig. 2 sTREM2 promotes microgliosis in 5×FAD mice and microglial migration. a The hippocampus was dissected from vehicle- or sTREM2-injected 5×FAD
mice. After RNA extraction, the relative mRNA levels of Iba1 and GFAP in the hippocampus shown as a bar graph were determined by quantitative real-
time PCR. β-actin was used as an internal control (n= 4 mice per group, paired Student’s t test). b Iba1 and GFAP proteins were analyzed by Western
blotting 7 days after sTREM2 injection to the hippocampus of 5×FAD mice. c Quantitation of the protein levels of Iba1 and GFAP in b (n= 4 mice per group,
paired Student’s t test). d Coronal sections from injected 5×FAD mice were stained with DAPI (blue) for nuclei, Ki67 (green) for proliferating cells, and Iba1
(red) for microglia. Representative z-stack images of the hippocampus regions are shown. Original magnification ×20; scale bar, 100 μm. Images on the
right represent enlarged Ki67-positive cells with a scale bar equal to 20 μm. e Quantitation of the number of Iba1-positive cells in d (n= 5 mice, 22 fields
of each group for analysis, paired Student’s t test). f Quantitation of the number of proliferating microglial cells, as indicated by the co-staining of Ki67
and Iba1 (Iba1+Ki67+) (n= 5 mice, 22 fields of each group for analysis, paired Student’s t test). g Primary microglial cells (105) from WT mice were
plated onto transwell chamber inserts. Following 24-h incubation with vehicle (PBS), native sTREM2 protein (100 nM), or heat-inactivated sTREM2 protein
(100 nM), cells migrated through the membrane were stained with hematoxylin and eosin and imaged under a Nikon inverted microscope. Scale bar,
100 µm. h Quantitation of the number of migrated cells (n= 9 from three independent experiments, one-way ANOVA). All data are presented as mean ±
SEM. *p < 0.05; **p < 0.01; ****p < 0.0001; ns, not significant
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(mEPSCs) and miniature inhibitory postsynaptic currents
(mIPSCs). The amplitude and frequency of both mEPSCs and
mIPSCs did not significantly differ between Fc- and sTREM-Fc-
treated groups (Supplementary Fig. 4h–k). Furthermore, sTREM2
did not affect the abundance of synaptic proteins in the primary
neuronal cultures (Supplementary Fig. 4l, m), suggesting that
sTREM2 does not directly modulate synaptic plasticity and
function. Taken together, these data indicate that microglia play
an indispensable role in mediating the protective effects of
sTREM2 on amyloid plaque pathology and synaptic plasticity.
Validation with physiologically produced sTREM2. At the time
we started this project, the precise TREM2 cleavage site to
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generate sTREM2 was unknown. More recently, it was reported
that TREM2 undergoes regulated shedding at the H157–S158
peptide bond, resulting in the liberation of soluble TREM2 ending
at position 157 (sTREM2-157)35–37. Hence, we went on to test
whether the physiological form of sTREM2-157 protein recapi-
tulates the functions that we defined for the sTREM2-171 mimics
(Fig. 5a). Consistent with our previous findings43, the sTREM2-
157 protein was as efficient as the sTREM-171 in both suppres-
sing microglial apoptosis and stimulating the production of
inflammatory cytokines (Fig. 5b, c). Furthermore, the native
sTREM2-157 protein but not its heat-inactivated form sig-
nificantly stimulated the migration of microglial cells, consistent
with the role of sTREM2-171 protein as a chemoattractant for
microglia (Fig. 5d, e). Importantly, the sTREM2-157 protein
largely and significantly decreased the deposition of amyloid
plaques and promoted the clustering of microglia in the vicinity
of plaques (Fig. 5f–i). However, sTREM2 lost these protective
functions upon heat inactivation, indicating that the native pro-
tein structure is required for sTREM2 function (Supplementary
Fig. 5). We therefore conclude that the physiological form of
sTREM2 protein functions as efficiently as the sTREM2-171 in
modulating microglial responsiveness and decreasing plaque
deposition in 5×FAD mice.
Long-term expression of sTREM2 reduces Aβ pathology. To
validate the findings from recombinant sTREM2 protein and to
further assess the long-term impact of sTREM2 on AD-related
pathology, we expressed sTREM2 in the brain of 5×FAD mice
using AAV-mediated expression approach. Viruses carrying
cDNAs encoding EGFP alone as a control or EGFP-2A-sTREM2-
3×FLAG (spanning N-terminal amino acids 1–171 of TREM2)
were injected into the cerebral ventricles of P0 neonatal 5×FAD
mice. Seven months after viral injection, we found similar dis-
tribution patterns of EGFP expression in control and sTREM2-
injected brains, including the cortex and hippocampus (Supple-
mentary Fig. 6a). By analyzing potential colocalization of
sTREM2 with cell-type-specific markers for astrocytes, microglia,
and neurons, we found that the sTREM2 signal was colocalized
primarily with NeuN-positive neurons, but not with GFAP-
positive astrocytes or Iba1-positive microglia (Supplementary
Fig. 6b). The absence of AAV infection to microglial cells is
consistent with the previous observation that microglia are
refractory to AAV49. Transduction of primary neurons with the
sTREM2 expression construct showed that sTREM2 was effi-
ciently secreted into the media (Supplementary Fig. 6c, d). Thus,
sTREM2 possesses the tendency to contact any cell type in the
brain, including microglia, after releasing into the extracellular
space. The mRNA levels of sTREM2 in the cerebral cortex and
hippocampus were significantly increased in 5×FAD mice, as
compared with the EGFP control (Fig. 6a). This increase was
further confirmed at the protein level using ELISA to measure the
levels of sTREM2 in the TBS-soluble fractions (Fig. 6b).
We next evaluated the effects of sTREM2 expression on
Aβ levels and plaque deposition. We found that sTREM2
significantly decreased the total plaque burden in both the
hippocampus and the cortex of sTREM2-expressing 5×FAD
mice relative to controls (Fig. 6c, d). Congo red-positive dense
core compact plaques were also reduced in the presence of AAV-
mediated sTREM2 expression (Supplementary Fig. 7a, b). To
further analyze how sTREM2 affects the dynamic pools of Aβ, we
examined Aβ levels in sequentially extracted tris-buffered saline
(TBS)-soluble, detergent-soluble (TBSX), and detergent-insoluble
(guanidine-HCl, GDN) fractions from cortical and hippocampal
mouse brain tissues by ELISA50. The majority of Aβ in these
mice at 7 months of age was fractioned in the detergent-
insoluble fractions, reflecting its deposition in the amyloid plaque
(Supplementary Fig. 7c, d). Consistent with decreased Aβ
deposition, the concentrations of insoluble Aβ42 in the guanidine
fractions were significantly lower in the cortex and hippocampus
of sTREM2-expressing 5×FAD mice than the control. There were
no changes in Aβ levels in TBS-soluble and TBSX-soluble
fractions. Furthermore, AAV-mediated sTREM2 expression had
no significant effects on the levels of APP, its cleavage products,
or Aβ-degrading enzymes, consistent with the effects that we
observed using a recombinant sTREM2 protein (Supplementary
Fig. 7e–g). In the presence of sTREM2 expression, the number of
plaque-associated microglia was significantly increased in both
the hippocampus and the cortex of 5×FAD mice (Fig. 6e, f).
Taken together, AAV-mediated sTREM2 expression ameliorates
plaque deposition and enhances microglial enrichment in the
vicinity of an amyloid plaque.
AAV-mediated sTREM2 expression rescues behavioral deficits.
We further evaluated if the beneficial effects of sTREM2
expression in reducing amyloid plaque deposition are associated
with improved synaptic plasticity and cognitive function of
5×FAD mice. To analyze the potential impacts of sTREM2
expression on AD-related behavioral deficits, the spatial learning
and memory function of experimental mice were evaluated by
the Morris water maze 6 months after viral injection. Similar
to the 5×FAD mice, the mRNA and protein levels of sTREM2 in
the cerebral cortex and the hippocampus detected 7 months after
AAV injection were significantly increased in WT mice (Fig. 7a,
b). The 5×FAD mice were less efficient at finding the hidden
platform than WT mice, indicating a deficit in spatial learning
ability at 6 months of age (Fig. 7c). Importantly, sTREM2
expression rescued this spatial learning deficit, as evidenced by a
reduced latency to reach the platform over the 7 days of training.
Fig. 3 sTREM2 enhances microglial phagocytosis and degradation of Aβ. a Coronal sections from sTREM2-injected 5×FAD mice were stained with DAPI
(blue) for nuclei, MOAB-2 (green) for Aβ, or CD68 (red) for a phagocytic phenotype of microglia. Three-dimensional reconstruction of Aβ, CD68, and Aβ
colocalized with CD68 was shown. Scale bar, 25 μm. b Quantitation of the ratio of Aβ colocalized with CD68 within each plaque (n= 6 mice, 42 plaques of
vehicle and 30 plaques of sTREM2 for analysis, paired Student’s t test). c Representative FACS dot plots of microglia or macrophage from WT or 5×FAD
mice are shown. Microglia and microphage were identified as CD11b+CD45low and CD11b+CD45high, respectively. d Quantitation of the cell population of
microglia or macrophage in c (n= 8 mice, paired Student’s t test). e Representative FACS dot plots showing the microglial phagocytosis of Aβ in 5×FAD
mice. f Quantification of the percentage (%) of methoxy-X04+CD11b+CD45low hippocampal microglial cells by flow cytometry isolated from sTREM2-
injected 5×FAD mice (n= 8 mice, paired Student’s t test). g Representative histogram displaying background fluorescence (negative) of untreated
microglia and the distribution of FAM-Aβ42-positive cells treated with vehicle or sTREM2 protein. h Quantitation of the mean fluorescence in g to indicate
the amount of FAM-Aβ42 uptake. Values were normalized to the vehicle control without cyto D (n= 9 from three independent experiments, two-way
ANOVA, Bonferonni post hoc analyses). i The amounts of cell-associated Aβ42 were quantified by ELISA (n= 12 from four independent experiments, two-
way ANOVA, Bonferonni post hoc analyses). j The amounts of degraded Aβ42 were calculated by subtracting the cell-associated Aβ in the absence of
inhibitors from that in the presence of inhibitors (n= 12 from four independent experiments, unpaired Student’s t test). All data are presented as mean ±
SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant
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Fig. 4 Depletion of microglia attenuates the protective effects of sTREM2 on Aβ pathology and synaptic plasticity. a Scheme for PLX3397 administration
and sTREM2 injection in 5×FAD mice. b The 5×FAD mice were fed with either PLX3397 or control chow for 14 days and then injected with either sTREM2
protein or vehicle control. After continued feeding with PLX3397 or control chow for 7 days, coronal sections were stained with DAPI (blue) for nuclei,
MOAB-2 (green) for Aβ, and Iba1 (red) for microglia. Representative images of the hippocampus region are shown. Original magnification ×20; scale bar,
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paired Student’s t test). All data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant
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During the probe trials conducted 24 h after the last training,
the 5×FAD mice receiving sTREM2 viruses spent significantly
more time in the target quadrant than those receiving control
viruses (Fig. 7d). However, expression of sTREM2 did not affect
the spatial memory of WT mice in either the hidden platform
tests or probe trials (Fig. 7c, d). As controls, swim speeds were
comparable in all groups of animals, thus excluding impairments
in motor function (Fig. 7e). These data indicate that sTREM2
expression could rescue the spatial memory impairments in
5×FAD mice.
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We next examined whether sTREM2-mediated memory
improvement in 5×FAD mice was reflected at the synaptic level.
We thus studied the hippocampal synaptic plasticity in the same
set of animals as used for the behavioral study. Consistent with
previous studies, the 5×FAD mice showed significantly impaired
LTP as compared with WT mice (Fig. 7f, g)51. Importantly, the
magnitude of LTP measured during the last 10min post induction
(51–60min) was significantly higher in sTREM2-expressing
5×FAD mice relative to control mice (Fig. 7g). However, sTREM2
expression had a minimal effect on hippocampal LTP in WT mice.
Thus, AAV-mediated expression of sTREM2 largely and specifi-
cally ameliorated LTP deficits in 5×FAD mice. Taken together, our
study reveals that sTREM2 expression could rescue or ameliorate
key Aβ/amyloid-induced AD phenotypes, including defective
synaptic plasticity and impaired spatial memory.
Discussion
Although it has been widely acknowledged that the CSF levels of
sTREM2 are elevated in AD, it remains unknown how sTREM2
impacts the amyloid pathology and microglial behaviors in the
disease context. In the present study, we demonstrated for the
first time that sTREM2 is capable of reducing amyloid deposition,
ameliorating synaptic impairments and memory deficits in the
5×FAD mouse model. Intriguingly, these protective effects of
sTREM2 were attenuated by the depletion of microglia, suggest-
ing a crucial role for microglia in mediating sTREM2 function.
Indeed, sTREM2 enhances a variety of microglial activities known
to control amyloid pathology, including microgliosis, migration,
clustering in the vicinity of an amyloid plaque, as well as uptake
and degradation of Aβ. As the accumulation and deposition of Aβ
in the brain likely drives the pathogenic cascades of AD4,52,53, our
study provides a critical link between Aβ pathology and the
emerging role of microglia-mediated innate immune response in
the pathogenesis of AD54,55.
Recent studies have begun to unravel the specific roles of
TREM2 in modulating microglial functions. For example, the
deficiency of TREM2 has been shown to decrease the number of
plaque-associated microglia, reduce plaque compaction, and
axonal dystrophy11,56. The TREM2 signaling pathways also play
key roles in regulating Aβ uptake by microglial cells; loss of
TREM2 results in reduced phagocytosis, while increased TREM2
gene dosage enhances phagocytic activity11,57. Intriguingly, the
above-mentioned functions as well as the effects on microglial
proliferation and migration by full-length TREM2 are well reca-
pitulated by sTREM2. Since the soluble version of another TREM
family member TREM1 was found to negatively modulate
TREM1 signaling, initially, sTREM2 was postulated to similarly
compete with its membrane-bound form to block TREM2 func-
tion. Nevertheless, our data suggest that sTREM2 possesses
important biological and pathological roles other than acting as a
decoy receptor opposing full-length TREM2 signaling.
Although many functional aspects of sTREM2 resemble those of
membrane-bound TREM2, they are not identical. The biological
actions of sTREM2 do not require the presence of full-length
TREM2 or its intracellular adapter DAP1243. Moreover, the full-
length TREM2 has been found to promote the formation of a
neuroprotective microglia barrier that regulates amyloid compac-
tion and insulation, thereby reducing axonal dystrophy around
amyloid deposits. Despite a clear reduction of plaque deposition
and the total area of dystrophic neurites by sTREM2, it does not
significantly impact the amount of dystrophic neurites per plaque
and thus unlikely contributes to compacting amyloid fibrils (Fig. 1).
Recently, comprehensive single-cell RNA analysis of CNS immune
cells in neurodegenerative conditions has discovered an essential
role of TREM2 in the activation of disease-associated microglia58,59.
In future studies, it will be informative to perform transcriptomics
analysis at the single-cell level to examine how sTREM2 modulates
microglial gene expression in the diseased brain.
A recent study reported that sTREM2 released from cell
membranes latches onto amyloid plaque and nearby neurons42,
indicating a direct physical interaction between sTREM2 and
amyloid plaques/neurons. In fact, we have found that an oligo-
meric Aβ42 specifically binds to sTREM2 with a high affinity26,27.
In addition, sTREM2 also binds to apoE, another major com-
ponent of amyloid plaques23–25. Hence, sTREM2 is likely present
in amyloid plaques and acts as a chemoattractant for microglial
recruitment to the vicinity of a plaque. Although sTREM2 has
been reported to co-localize with neurons in vivo, incubation of
primary neuronal cultures with sTREM2 in the absence of
microglia had minimal effects on the abundance of the synaptic
proteins or the amplitude and frequency of both mEPSCs and
mIPSCs (Supplementary Fig. 4). However, sTREM2 significantly
increased the levels of several synaptic proteins and rescued the
impaired LTP when administered to the brains of 5×FAD mice
(Fig. 4). Intriguingly, the protective effects of sTREM2 on amyloid
load and synaptic function were attenuated by the presence of a
selective CSF1R kinase inhibitor, PLX3397, which nearly elim-
inates microglia from the 5×FAD mice (Fig. 4). Hence, our data
support that microglia are the main effector cells that mediate the
protective functions of sTREM2 in the context of AD. However,
the microglial surface receptor(s) for sTREM2 remain unknown.
Considering the fact that TREM2 is a highly promiscuous
receptor engaging a wide array of ligands, the receptor(s) for
sTREM2 might also be highly redundant and needs to be sys-
tematically investigated in future studies.
Fig. 5 The physiological form of sTREM2 protein modulates microglial responsiveness and decreases plaque deposition. a The purified sTREM2-157 and
sTREM2-171 proteins were analyzed by silver staining. b Primary microglia were cultured with 40 nM sTREM2-157 or sTREM2-171 protein for 24 h
after GM-CSF withdrawal. TUNEL staining was then performed and the number of TUNEL-positive cells were quantified (n= 6 from three independent
experiments, one-way ANOVA). c Primary microglia were treated with 40 nM sTREM2-157 or sTREM2-171 protein for 4 h. The relative mRNA levels of
IL-1β, IL-6, and TNF shown as bar graphs were determined by quantitative real-time PCR. β-actin was used as an internal control (n= 3 per group, one-way
ANOVA). d Primary microglial cells were plated onto transwell chamber inserts. Following 24-h incubation with vehicle (PBS), native sTREM2-157 protein
(100 nM), or inactive sTREM2-157 protein (100 nM), cells migrated through the membrane were imaged under a Nikon inverted microscope. Scale bar,
100 µm. e Quantitation of the number of migrated cells in d (n= 9 from three independent experiments, one-way ANOVA). f Coronal sections from
5×FAD mice injected with either sTREM2-157 protein or vehicle control were stained with DAPI (blue) for nuclei, MOAB-2 (green) for Aβ, and Iba1 (red)
for microglia. Representative images of the hippocampus region are shown. Original magnification ×20; scale bar, 100 μm. g Quantitation of amyloid plaque
deposition in f (n= 6 mice, 24 fields of each group for analysis, paired Student’s t test). h Coronal sections from sTREM2-157-injected 5×FAD mice
were stained with DAPI (blue) for nuclei, MOAB-2 (green) for Aβ, and Iba1 (red) for microglia. Representative z-stack images of the hippocampus region
are shown. Scale bar, 25 μm. i Quantitation of the number of plaque-associated microglia in h (n= 6 mice, 47 plaques of vehicle and 40 plaques of sTREM2
for analysis, paired Student’s t test). Plaques with 50 μm in diameter were selected for analysis. All data are presented as mean ± SEM. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001; ns, not significant
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Although the precise mechanism mediating the ability of
sTREM2 to attenuate AD pathology remains to be determined,
we speculate that significantly reduced levels of Aβ and plaque
load upon sTREM2 treatment may contribute to the rescue of
synaptic failure and memory deficits in the case of long-term
sTREM2 exposure (AAV-mediated sTREM2 expression). How-
ever, it is unlikely that the decreased amyloid plaque is respon-
sible for improved LTP in brain slices that were treated with
sTREM2 for only 1 h. There are several previous studies that have
linked microglia-related functions to synaptic plasticity. For
example, Parkhurst et al. showed that microglia promote
learning-induced formation of glutamatergic synapses and that
this effect is mediated by microglia-released brain-derived neu-
rotrophic factor60. In addition, it has been demonstrated that
TNF and IL-1β released by microglial cells enhance synaptic
transmission and neuronal activity61–63. Our current study has
clearly shown that sTREM2 exerts its effects in a microglia-
dependent manner. Thus, it is possible that sTREM2 positively
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modulates synaptic plasticity by promoting neurotrophic func-
tions of microglia. Taken together, our data suggest that sTREM2
might exert its protective functions in AD by both amyloid-
dependent and amyloid-independent pathways.
In conclusion, our data provide strong evidence that sTREM2
is crucially involved in regulating microglial dynamics to
control amyloid plaque development and synaptic plasticity.
Although the precise mechanistic underpinnings of the disease-
modulating effects require further investigation, our findings shed
new light on the roles of sTREM2 in AD, and suggest that
elevation of sTREM2 represents a protective response against
AD pathology.
Methods
Mice. All animal experiments were approved by the Animal Ethics Committee of
the Xiamen University and were conducted in compliance with all relevant ethical
regulations for animal testing and research. Sample sizes were adequately powered
to observe the effects on the basis of past experience of animal studies43,64. Mice
Fig. 6 AAV-mediated sTREM2 expression reduces amyloid plaque deposition and increases the number of plaque-associated microglia. a, b AAV-
mediated sTREM2 expression in 5×FAD mice. Neonatal 5×FAD mice were injected with either AAV2/8-CAG-EGFP (Ctrl) or AAV2/8-CAG-EGFP-2A-
sTREM2-3×FLAG (human TREM2 1–171 aa) (sTREM2) in the cerebral ventricles and analyzed after 7 months for sTREM2 expression at the mRNA (a, n=
8 mice per group, unpaired Student’s t test) or protein (b, n= 8 mice for Ctrl, n= 9 mice for sTREM2, unpaired Student’s t test) levels in the cortex and
hippcampus using RT-qPCR or ELISA, respectively. c The 5×FAD mice injected with control AAV or AAV-sTREM2 were analyzed for amyloid plaque
pathology using an anti-Aβ antibody MOAB-2. Representative images of the hippocampus and the cortex of those mice are shown. Original magnification
×10; scale bar, 200 μm. Blue, DAPI; red, Aβ antibody MOAB-2. d Quantitation of Aβ plaque area in the hippocampus and cortex of 5×FAD mice injected
with either control AAV or AAV-sTREM2 (n= 5 mice per group for the hippocampus or the cortex, 12 fields of the hippo and 28 fields of the cortex for
analysis, unpaired Student’s t test). e Coronal sections from the 5×FAD mice injected with control AAV or AAV-sTREM2 were stained with DAPI (blue) for
nuclei, MOAB-2 (green) for an amyloid plaque, and Iba1 (red) for microglia. Representative z-stack images of the hippocampus and cortex region are
shown. Scale bar, 25 μm. f Quantitation of the number of plaque-associated microglia in e (n= 5 mice, 35 plaques of ctrl and 37 plaques of sTREM2 in the
hippocampus or 64 plaques of ctrl and 67 plaques of sTREM2 in the cortex for analysis, unpaired Student’s t test). Plaques with 50 μm in diameter were
selected for analysis. All data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001
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Fig. 7 AAV-mediated sTREM2 expression rescues behavioral and LTP deficits in 5×FAD mice. a, b Neonatal WT mice were injected with either control
AAV or AAV-sTREM2 in the cerebral ventricles and analyzed after 7 months for sTREM2 expression at the mRNA (a, n= 6 mice for Ctrl in hippo or cortex,
n= 6 mice for sTREM2 in hippo and n= 5 mice for sTREM2 in the cortex, unpaired Student’s t test) or protein (b, n= 6 mice per group, unpaired Student’s
t test) levels in the cortex and hippcampus using RT-qPCR or ELISA, respectively. c–e Morris water maze tests were performed in wild-type (WT) or
5×FAD mice 6 months after injection of either control AAV or AAV-sTREM2 (n= 12 mice for WT-Ctrl, n= 19 mice for WT-sTREM2, n= 11 mice for
5×FAD-Ctrl, and n= 10 mice for 5×FAD-sTREM2, two-way ANOVA, Bonferonni post hoc analyses). The escape latency time to reach the hidden platform
was recorded during the 7-day training (c). Probe trial was performed 24 h after the last trial of a hidden platform task and the percentage of search time
for each quadrant was recorded (d). Swimming speed of each group was recorded during the probe trial (e). f Time course of fEPSP measures recorded in
the hippocampal CA1 region before and after 100-Hz stimulation in the Schaffer collateral region in slices fromWT or 5×FAD mice 7 months after receiving
control AAV or AAV-sTREM2. Normalized fEPSP slopes were plotted every 1 min for each group. g The averaged fEPSPs recorded 50–60min after
induction of LTP (n= 8 slices for WT-Ctrl, n= 10 slices for WT-sTREM2, n= 6 slices for 5×FAD-Ctrl, and n= 8 slices for 5×FAD-sTREM2, at least three
mice per group, two-way ANOVA, Bonferonni post hoc analyses). All data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not
significant
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were randomly selected for further biological analysis, and the investigators were
blinded to group allocation during the experiments or outcome assessments.
For AAV injection, postnatal P0 mice within each genotype (WT or 5×FAD
mice) were injected with control AAV or AAV-sTREM2, and both males and
females were used in this study. The behavioral tests were performed at 6 months
of age. For LTP and biochemical analysis, samples were harvested from AAV-
injected WT or 5×FAD mice at 7 months.
For sTREM2 protein injection, 5×FAD mice at 7 months of age were injected
with control (PBS or heat-inactivated sTREM2) or native sTREM2 protein into
the left and right hippocampi, respectively. Seven days after injection, mice
were anesthetized and perfused with ice-cold PBS. Samples were harvested for
biochemical or histological analysis. Both males and females were used in this
study.
To pharmacologically ablate microglia in the brain, 6-month-old (for LTP) or
7-month-old (for amyloid plaque) 5×FAD mice were fed with PLX3397 (Selleck,
S7818, 290 mg/kg formulated in standard chow)47,48. Age-matched control groups
were fed with the same standard chow but without PLX3397.
Injection of AAV. The AAV2/8 viruses expressing human EGFP-2A-sTREM2-
3×FLAG (1–171aa) (AAV-sTREM2) or EGFP (control AAV) under the control of
the CAG promoter were generated by Obio Technology (Shanghai). Neonatal mice
were cryoanesthetized on ice for 3 min before AAV injection. Following cessation
of movement, viruses were injected into the lateral ventricles of both cerebral
hemispheres with 7.5 × 109 total viral particles per side using a 10-μL syringe
(Hamilton, 7642-01) with a 30-G needle (Hamilton, 7803-07). After both injections
were complete, pups were placed on a warming pad until they regained normal
color and resumed movement. All injected pups were then returned to their
mothers for care and further recovery.
Tissue preparation. Mice were anesthetized and transcardially perfused with
50 mL of ice-cold 1× PBS. Brains were removed and dissected at the midline.
For biochemical analysis, the cortex and hippocampus were dissociated and
immediately snap-frozen in liquid nitrogen and stored at −80 °C for extraction of
protein and RNA. For immunohistochemistry analysis, brains were fixed in 4%
paraformaldehyde (PFA, Sigma-Aldrich, P1468) overnight at 4 °C, followed by
transferring to 30% sucrose at 4 °C for 48 h, before being embedded for cryostat
sectioning.
Western blotting. Samples were homogenized and incubated in RIPA Lysis and
Extraction Buffer (Thermo Fisher Scientific, 89900), supplemented with Protease
and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 78440). Protein
concentrations were determined using the BCA Protein Assay Kit (Thermo Fisher
Scientific, 23225) according to the manufacturer’s instruction. Equal amounts of
total proteins were resolved by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis and transferred to PVDF membranes (Millipore, IPVH00010). After
blocking, the membranes were blotted by a primary antibody and detected with
horseradish peroxidase-conjugated secondary antibody. Proteins were visualized
using ECL Western blotting detection reagents (Millipore, WBKLS0500). Immu-
noreactive bands were quantified using ImageJ software. The following antibodies
were used: anti-Iba1 (Wako, 016-20001, 1:500), anti-GFAP (Cell Signaling Tech-
nology, 3670S, 1:1000), anti-NR2A (Millipore, 07-632), anti-NR2B (DB Bios-
ciences, 610416, 1:1000), anti-NR1 (Cell Signaling Technology, 5704S, 1:1000),
anti-GluR1 (Millipore, MAB2263, 1:1000), anti-GluR2 (Millipore, AB1768-I,
1:1000), anti-PSD95 (Cell Signaling Technology, 3450S, 1:2000), anti-vGluT1
(Millipore, MAB5502, 1:2000), anti-Synaptophysin (Sigma-Aldrich, S5768, 1:2000),
anti-APP C-terminal (36965, in-house, 1:1000), anti-TREM2 (R&D Systems,
AF1828, 1:500), and anti-α-Tubulin (Millipore, MABT205, 1:3000).
RNA isolation and real-time quantitative PCR analysis. Total RNA was isolated
from the cortex or the hippocampus using TRIzol reagent (Thermo Fisher Sci-
entific, 15596018). One microgram of RNA was reverse transcribed into the first-
strand cDNA using cDNA Synthesis SuperMix (TransGen Biotech, China, AT314-
02) according to the manufacturer’s protocol. Quantitative PCR was performed
using the FastStart Universal SYBR Green Master mix (Roche, 04913914001). The
real-time PCR was performed on 7500 fast (ABI) or 480 LightCycler (Roche). The
primer sequences were as follows: Iba1-Forward: GTCCTTGAAGCGAATGCTG
G, Iba1-Reverse: CATTCTCAAGATGGCAGATC; GFAP-Forward: TCCTGGA
ACAGCAAAACAAG, GFAP-Reverse: CAGCCTCAGGTTGGTTTCAT;
IL-1β-Forward: GCAACTGTTCCTGAACTCAACT, IL-1β-Reverse: ATCTT
TTGGGGTCCGTCAACT; IL-6-Forward: CAATGGCAATTCTGATTGTATG,
IL-6-Reverse: AGGACTCTGGCTTTGTCTTTC; TNF-Forward: CCCTCACA
CTCAGATCATCTTCT, TNF-Reverse: GCTACGACGTGGGCTACAG; sTREM2-
Forward: AACTTGTGGCTGCTGTCCTT, sTREM2-Reverse: GGTAGAGACCCG
CATCATGG; IDE-Forward: AATCCGGCCATCCAGAGAATA, IDE-Reverse:
GGGTCTGACAGTGAACCTATGT; NEP-Forward: CTCTCTGTGCTTGTCTTG
CTC, NEP-Reverse: GACGTTGCGTTTCAACCAGC; ECE1-Forward: CAGGTG
GTCACAGCTCACTAC, ECE1-Reverse: GGTATCCAGTCAGGACCTTTTCA;
MMP2-Forward: CAAGTTCCCCGGCGATGTC, MMP2-Reverse: TTCTGG
TCAAGGTCACCTGTC; MMP9-Forward: GCAGAGGCATACTTGTACC,
MMP9-Reverse: TGATGTTATGATGGTCCCACTTG.
Microglial migration in transwell assays. Mixed glial cultures were isolated from
WT mice at postnatal day 1–2 and were plated onto poly-l-lysine-coated flasks and
grown in DMEM supplemented with 10% fetal bovine serum (FBS) (Gibco). After
3 days, the medium was changed to that which contained 25 ng/ml granulocyte-
macrophage CSF (GM-CSF) and 10% FBS. Primary microglial cells were harvested
by shaking after 10–12 days in culture and once every 3 days thereafter (up to four
harvests). Microglial migration assay was performed in transwell cell culture inserts
with a 8-μm pore (Costar, 3422). Primary microglial cells (105) suspended in
100 μL of serum-free DMEM were added to the upper chamber of the inserts with
600 μL of serum-free DMEM in the bottom chamber. After 1-h incubation at 37 °C
and 5% CO2, the bottom medium was replaced with DMEM containing PBS
(vehicle), 100 nM native sTREM2, or heat-inactivated sTREM2 and the culture
continued for 24 h. For analysis of the migrated cell number, cells remaining on the
upper surface of the membrane were removed by scraping with a cotton swab and
the inserts were washed three times with PBS. Cells were then fixed with 4% PFA
for 20 min, followed by staining with hematoxylin and eosin. The total number of
cells on the membrane without scraping was also counted in separate wells and the
quantification for the microglial migration was normalized to the total final
number of cells.
ELISA analyses. For Aβ ELISA, the cortex or the hippocampus was sequentially
extracted with TBS, TBSX, and guanidine-HCl (GDN)50. The levels of Aβ40 or
Aβ42 were measured using sandwich ELISA techniques with monoclonal antibody
(mAb) 2.1.3 (human Aβx-42 specific, 20 μg/mL, in-house) and mAb 13.1.1 (human
Aβx-40 specific, 20 μg/mL, in-house) for capture and horseradish peroxidase
(HRP)-conjugated mAb Ab5 (human Aβ1-16 specific, 1 μg/mL, in-house) for
detection64. The ELISA was developed using ELISA TMB (Sigma-Aldrich, T8665).
Synthetic human Aβ40 (AnaSpec, AS-24236) or Aβ42 peptide (AnaSpec, AS-
20276) was used to generate the standard curves for each assay. Human or mouse
sTREM2 ELISA assay was established in-house. A 96-well plate was coated with a
TREM2 antibody (R&D Systems, MAB17291-100, 1:1000) in coating buffer (0.05
M Carbonate buffer, pH 9.6) overnight at 4 °C. The plate was then blocked in
blocking buffer (1% Block Ace in PBS) for 4 h at room temperature (RT), subse-
quently washed three times with PBS, and incubated with samples diluted 1:5 with
assay buffer (0.2% bovine serum albumin and 0.05% Tween 20 in PBS) overnight
at 4 °C. Plates were washed five times with wash buffer (0.05% Tween 20 in PBS)
before incubation for 2 h at RT with human TREM2 biotinylated antibody (R&D
Systems, BAF1828, 1:3000) or mouse Trem2 biotinylated antibody (R&D Systems,
BAF1729, 1:3000). After the washing steps, the plates were incubated with Strep-
tavidin Poly-HRP40 Conjugate (Fitzgerald, 65R-S104PHRP, 1:3000) for 1 h in the
dark. After five additional washing steps, the plates were developed by adding the
TMB substrate (Sigma-Aldrich, T5569) and read at 620 nm on a Varioskan Flash
Multimode Reader (Thermo Fisher Scientific).
Immunohistochemistry and microscopy. Mouse coronal sections were cut
(12-µm thick) with a cryostat and mounted on poly-L-lysine precoated glass slides,
air-dried overnight at 37 °C, and subsequently processed for staining. The sections
were washed in 1× PBS for 15 min and incubated with blocking buffer (PBS with
5% normal donkey serum and 0.2% Triton X-100) for 1 h at RT, followed by
incubation with primary antibodies for 48 h at 4 °C and the Alexa-fluorophore-
conjugated secondary antibodies (Thermo Fisher Scientific, A-21203, A-21202, A-
21207, A-21244, or A-21247, 1:400) for 2 h at RT in the dark. Sections were washed
and sealed with an anti-fade reagent (Life Technologies, P36935). For confocal
microscopy, a NIKON A1R Plus confocal microscope was used to acquire all
images; laser and detector settings were maintained constant in the same experi-
ment. For analysis of the amyloid plaque-associated microglia, 6-μm z-stacks
(consisting of 13 optical slices of 0.5-μm thickness) were acquired and the max-
imum intensity projections were generated. To examine the colocalization of an
amyloid plaque and CD68, 6-μm z-stacks (consisting of 13 optical slices of 0.5-μm
thickness) were acquired and 3D reconstruction was conducted using the Imaris
software (Bitplane). The following antibodies of immunohistochemistry detection
were used in this study: anti-Iba1 (Wako, 019-19741, 1:200), anti-Aβ (MOAB-2,
Abcam, ab126649, 1:400), anti-TREM2 (R&D Systems, AF1828, 1:50), anti-Lamp1
(DB Biosciences, 553792, 1:50), anti-Ki67 (ThermoFisher, 14-5698-82, 1:50), anti-
CD68 (Bio-Rad, MCA1957, 1:50), anti-NeuN (R&D Systems, MAB377, 1:100),
and anti-GFAP (R&D Systems, AB5804, 1:800).
Brain stereotaxic injection. The 5×FAD mice at 7 months of age were anesthe-
tized and placed in a stereotaxic frame, a skin incision was made, and holes were
drilled at x (±2.0 mm from bregma) and y (−2.0 mm from bregma). A total of 6 μg
of sTREM2 protein in 2.0 μL of PBS, or heat-inactivated sTREM2 in 2.0 μL of PBS,
or 2.0 μL of PBS alone was delivered at 0.20 µL/min at z-depths of 2.0 mm to the
right and left hemispheres, respectively. The syringe was left in place for 10 min
after each injection before being withdrawn slowly. Seven days after injection, mice
were anesthetized and perfused with ice-cold PBS. For biochemical analysis, hip-
pocampi from the left or the right brain were dissected out, snap-frozen in liquid
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nitrogen, and stored at −80 °C for extraction of protein and RNA. For histologic
analysis, brains were fixed in 4% PFA overnight at 4 °C and transferred to 30%
sucrose for 48 h before being embedded for cryostat sectioning.
Aβ phagocytosis assays. For the in vitro assay, primary microglial cells were
seeded into 12-well culture plates at a density of 2 × 105 cells per well and were
cultured for 24 h after GM-CSF withdrawal. Cells were treated with 160 nM
sTREM2 protein in serum-free DMEM for 12 h, followed by treatment with a
phagocytosis inhibitor cytochalasin D (Calbiochem, 250255, 10 µM) for 30 min and
incubation with 500 nM FAM-Aβ42 oligomer for an additional 3 h. Cells were
trypsinized and washed with cold PBS for detection of FAM fluorescence using
fluorescence-activated cell sorting (FACS). The in vivo phagocytosis assay was
performed, as described previously with slight modifications66. The 7-month-old
5×FAD mice were injected with sTREM2 as described above. After 7 days, mice
were injected intraperitoneally with methoxy-X04 (Toris, 4920) at 10 mg/kg in 10%
DMSO/90% PBS (pH 12) for 3 h. Anesthetized mice were perfused with ice-cold
PBS and the hippocampi were isolated and chopped into pieces and digested in
DMEM/F12 containing 1 mg/mL Papain (Sigma, P4762), 1.2 U/mL Dispase II
(Sigma, D4693), 20 U/mL DNAse I (Sigma, D5025), and 100 U/mL Collagenase IV
(ThermoFisher, 17104019) at 37 °C for 30 min. The homogenization was achieved
by pipetting gently up and down. The homogenates were washed and filtered
through a 70-µm cell strainer. Hippocampal cells were centrifuged at 500 g for
5 min at 4 °C and resuspended in PBS. Cells were incubated with the Fc receptor
blocking antibody CD16/CD32 (BD Bioscience, 553141, 1:100) for 10 min at 4 °C
to prevent unspecific binding. Cells were washed once and then resuspended in
200 µL of PBS containing CD11b-APC (eBioscience, 17-0112-82, 1:100) and CD45-
FITC (eBioscience, 11-0451-85, 1:100) and incubated for 1 h at 4 °C. Cells were
washed again and resuspended in 2% FBS/PBS for FACS analysis. The frequencies
of viable methoxy-X04+CD11b+CD45low microglia were measured by flow cyto-
metry using a CytoFlex S (Beckman) and analyzed using FlowJo (Tree Star). WT
mice injected with methoxy-X04 were used as a control to determine the methoxy-
X04 threshold for non-phagocytosing cells.
Intracellular Aβ clearance. Primary microglia were treated with vehicle or
sTREM2 protein (160 nM) in serum-free DMEM medium for 12 h, followed by
treatment with lysosomal enzyme inhibitors (Pepstatin A: 10 µM, Leupeptin:
100 µM, and E-64d: 50 µM) or chloroquine (Sigma-Aldrich, C6628, 40 µM) for
30 min and incubation with a 500 nM Aβ42 oligomer for an additional 3 h. Cells
were harvested with trypsin and cell pellets were washed twice with PBS. Microglia
were lysed in lysis buffer (5 M guanidine in 50 mM Tris-HCl, pH 8.0). Lysates were
centrifuged at 13,400 g at 4 °C for 15 min. Supernatants were collected and further
used for quantifying the amounts of cell-associated Aβ42 using ELISA. The
amounts of degraded Aβ42 were calculated by subtracting the cell-associated Aβ
in the absence of inhibitors from that in the presence of inhibitors.
Electrophysiological recording. For LTP recording, experiments were performed,
as previously reported with modifications67. In brief, animals were deeply anes-
thetized with isoflurane and killed by decapitation. The brain was quickly removed
and dissected in an ice-cold cutting solution containing 64 mM NaCl, 2.5 mM KCl,
1.25 mM NaH2PO4, 10 mM MgSO4, 0.5 mM CaCl2, 26 mM NaHCO3, 10 mM
glucose, and 120 mM sucrose. Acute coronal slices (400 μm) were prepared using a
Vibroslice (VT 1000 S; Leica). Slices were allowed to recover for 30 min at 34 °C
and then at RT for at least 1 h before recording in the artificial CSF (aCSF)
containing 126 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM MgSO4, 2 mM
CaCl2, 26 mM NaHCO3, and 10 mM glucose. Slices were transferred to the
recording chamber and superfused with aCSF (2 mL/min) saturated with 95% O2/
5% CO2 (volume/volume) at 34 °C. For sTREM2 protein treatment, brain slices
were incubated with 50 nM recombinant sTREM2 protein for 1 h at RT, and
transferred to the chamber for LTP recording. fEPSPs were evoked every 20 s in the
CA1 stratum radiatum by stimulating the SCs/commissural pathway (for CA1)
with a bipolar stimulating electrode (FHC, Inc.) and recorded using a Multi-Clamp
700B amplifier (Molecular Devices) and Clampex10.5 acquisition software
(Molecular Devices) and digitized with Digidata 1550 A (Molecular Devices) with
glass pipettes (1–3 MΩ) filled with aCSF. Test stimuli consisted of monophasic 0.1-
ms pulses of constant currents (with intensity adjusted to produce 25% of the
maximum response) at a frequency of 0.05 Hz. After a 20-min-stable baseline was
established, LTP was induced in the CA1 area by two trains of 100-Hz stimuli with
the same intensity of the test stimulus. The strength of synaptic transmission was
determined by measuring the initial (20–80% rising phase) slope of fEPSPs.
Whole-cell voltage-clamp recordings were performed on cortical neurons
cultured for 12–14 DIV68. For sTREM2 protein treatment, neurons were incubated
with 50 nM recombinant sTREM2-Fc or Fc protein prepared as previously
described43 for 1 h, and transferred to the chamber for analysis. Recordings were
conducted in a submerged recording chamber perfused (1–1.5 mL/min) with aCSF
containing (in mM) 126 NaCl, 2.5 KCl, 1.2 NaH2PO4, 2.4 MgCl·6H2O, 1.2 CaCl2,
18 NaHCO3, and 11 Glucose, equilibrated with 95% O2 and 5% CO2 at RT. The
patch pipette (5–8MΩ) was filled with a standard intracellular solution containing
(in mM) 140 CsCH3SO3, 2 MgCl·6H2O, 5 TEA-Cl, 10 HEPES, 2.5 MgATP,
0.3 Na2GTP, and 1 EGTA, pH 7.2–7.4 (with CsOH). mEPSCs and mIPSCs were
recorded with 1 μM tetrodotoxin (TTX; Tocris, Cat. No. 1069) in voltage-clamp
mode at a holding potential of −70 mV and 0 mV, respectively. Series resistance
was monitored throughout the recording and was <30MΩ. Data were filtered at
2 kHz and sampled at 10 kHz. Whole-cell recording was made using patch-clamp
amplifiers (Multiclamp 700B). Data acquisition was performed using digitizers
(DigiData 1440A). mEPSC and mIPSC were analyzed off-line with MiniAnalysis
software (Synaptosoft Inc., Fort Lee, NJ).
Morris water maze. Experiments were conducted in a circular 120-cm-diameter
pool filled with opaque water kept at 21 °C. The mice were given four training trials
per day for 7 consecutive days, during which the platform was left in the same
position. The time taken to reach the platform (escape latency) was measured, and
the average of four trials was determined. If the mouse could not find the escape
platform within 60 s, it was placed on the platform for 10 s. A probe trail without a
platform was performed 24 h after the last trial of the hidden platform test. Per-
centage search time for each quadrant was recorded for 60 s. Mice were tracked
by a video camera (SONY) in both training and probe trials. Collected data were
analyzed by SMART 2.5 VIDEO TRACKING software (Panlab, Harvard
Apparatus).
Statistical analysis. All the electrophysiological data and histologic data analyses
were performed blindly. Statistical tests were performed using GraphPad Prism 5 or 6
(GraphPad Software, La Jolla, CA). Two-way ANOVA followed by Bonferonni post
hoc analyses or unpaired Student’s t test was used to analyze AAV and neuron data.
Paired Student’s t test was used to analyze sTREM2 protein-injected experiments. The
statistical method for each quantitated data was described in the Figure legend. All data
are shown as mean ± SEM and specific n values were reported in each Figure legend.
Levels of significance are as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
p < 0.05 was considered as stastically significant.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data underlying Figs. 1c, 1d, 1f, 1h, 1i, 2a, 2c, 2e, 2f, 2h, 3b, 3d, 3f, 3h, 3i, 3j, 4c, 4d,
4e, 4f, 4h, 4j, 5b, 5c, 5e, 5g, 5i, 6a, 6b, 6d, 6f, 7a, 7b, 7c, 7d, 7e, 7f, 7g, and Supplementary
Figs. 1a, 2a, 2b, 3a, 3b, 3c, 3d, 3e, 4b, 4c, 4d, 4e, 4f, 4g, 4i, 4k, 4l, 4m, 5c, 5e, 6c, 6d, 7b, 7c,
7d, 7e, 7f, 7g are provided as a Source Data file. All other data that support the findings of
this study are available from the corresponding author upon request.
Received: 7 September 2018 Accepted: 19 February 2019
References
1. Heneka, M. T. et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol.
14, 388–405 (2015).
2. Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T.
Neuropathological alterations in Alzheimer disease. Cold Spring Harb.
Perspect. Med. 1, a006189 (2011).
3. Holtzman, D. M., Morris, J. C. & Goate, A. M. Alzheimer’s disease: the
challenge of the second century. Sci. Transl. Med. 3, 77sr71 (2011).
4. Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade
hypothesis. Science 256, 184–185 (1992).
5. Yoon, S. S. & Jo, S. A. Mechanisms of amyloid-beta peptide clearance:
potential therapeutic targets for Alzheimer’s disease. Biomol.Ther. 20, 245–255
(2012).
6. Lee, C. Y. & Landreth, G. E. The role of microglia in amyloid clearance from
the AD brain. J. Neural Transm. 117, 949–960 (2010).
7. McGeer, P. L., Itagaki, S., Tago, H. & McGeer, E. G. Reactive microglia in
patients with senile dementia of the Alzheimer type are positive for the
histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79, 195–200
(1987).
8. Perlmutter, L. S., Barron, E. & Chui, H. C. Morphologic association between
microglia and senile plaque amyloid in Alzheimer’s disease. Neurosci. Lett.
119, 32–36 (1990).
9. Stalder, M. et al. Association of microglia with amyloid plaques in brains
of APP23 transgenic mice. Am. J. Pathol. 154, 1673–1684 (1999).
10. Condello, C., Yuan, P., Schain, A. & Grutzendler, J. Microglia constitute a
barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around
plaques. Nat. Commun. 6, 6176 (2015).
11. Yuan, P. et al. TREM2 haplodeficiency in mice and humans impairs the
microglia barrier function leading to decreased amyloid compaction and
severe axonal dystrophy. Neuron 90, 724–739 (2016).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09118-9
14 NATURE COMMUNICATIONS |         (2019) 10:1365 | https://doi.org/10.1038/s41467-019-09118-9 | www.nature.com/naturecommunications
12. Bertram, L. et al. Genome-wide association analysis reveals putative
Alzheimer’s disease susceptibility loci in addition to APOE. Am. J. Human
Genet. 83, 623–632 (2008).
13. Guerreiro, R. et al. TREM2 variants in Alzheimer’s disease. New Engl. J. Med.
368, 117–127 (2013).
14. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E,
EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease.
Nat. Genet. 43, 429–435 (2011).
15. Jin, S. C. et al. Coding variants in TREM2 increase risk for Alzheimer’s
disease. Human Mol. Genet. 23, 5838–5846 (2014).
16. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer’s
disease. New Engl. J. Med. 368, 107–116 (2013).
17. Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and
EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet. 43,
436–441 (2011).
18. Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate
microglial-mediated innate immunity in Alzheimer’s disease. Nat. Genet. 49,
1373–1384 (2017).
19. Efthymiou, A. G. & Goate, A. M. Late onset Alzheimer’s disease genetics
implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 43
(2017).
20. Schmid, C. D. et al. Heterogeneous expression of the triggering receptor
expressed on myeloid cells-2 on adult murine microglia. J. Neurochem. 83,
1309–1320 (2002).
21. Jay, T. R., von Saucken, V. E. & Landreth, G. E. TREM2 in neurodegenerative
diseases. Mol. Neurodegener. 12, 56 (2017).
22. Wang, Y. M. et al. TREM2 lipid sensing sustains the microglial response in
an Alzheimer’s disease model. Cell 160, 1061–1071 (2015).
23. Atagi, Y. et al. Apolipoprotein E is a ligand for triggering receptor expressed
on myeloid cells 2 (TREM2). J. Biol. Chem. 290, 26043–26050 (2015).
24. Bailey, C. C., DeVaux, L. B. & Farzan, M. The triggering receptor expressed
on myeloid cells 2 binds apolipoprotein E. J. Biol. Chem. 290, 26033–26042
(2015).
25. Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C. & Sheng, M. TREM2 binds
to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates
uptake of amyloid-beta by microglia. Neuron 91, 328–340 (2016).
26. Zhao, Y. et al. TREM2 is a receptor for beta-amyloid that mediates microglial
function. Neuron 97, 1023–1031 e1027 (2018).
27. Zhong, L. et al. Amyloid-beta modulates microglial responses by binding
to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol.
Neurodegener. 13, 15 (2018).
28. Gratuze, M., Leyns, C. E. G. & Holtzman, D. M. New insights into the role of
TREM2 in Alzheimer’s disease. Mol. Neurodegener. 13, 66 (2018).
29. Filipello, F. et al. The microglial innate immune receptor TREM2 is required
for synapse elimination and normal brain connectivity. Immunity 48, 979–991
e978 (2018).
30. Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in
Alzheimer’s disease. Cell 170, 649–663 e613 (2017).
31. Zheng, H. et al. TREM2 promotes microglial survival by activating Wnt/beta-
catenin pathway. J. Neurosci. 37, 1772–1784 (2017).
32. Zhong, L. et al. DAP12 stabilizes the C-terminal fragment of the triggering
receptor expressed on myeloid cells-2 (TREM2) and protects against LPS-
induced pro-inflammatory response. J. Biol. Chem. 290, 15866–15877 (2015).
33. Jay, T. R. et al. TREM2 deficiency eliminates TREM2+ inflammatory
macrophages and ameliorates pathology in Alzheimer’s disease mouse models.
J. Exp. Med. 212, 287–295 (2015).
34. Jay, T. R. et al. Disease progression-dependent effects of TREM2 deficiency
in a mouse model of Alzheimer’s Disease. J. Neurosci. 37, 637–647 (2017).
35. Feuerbach, D. et al. ADAM17 is the main sheddase for the generation of
human triggering receptor expressed in myeloid cells (hTREM2) ectodomain
and cleaves TREM2 after Histidine 157. Neurosci. Lett. 660, 109–114 (2017).
36. Schlepckow, K. et al. An Alzheimer-associated TREM2 variant occurs at
the ADAM cleavage site and affects shedding and phagocytic function.
Embo Mol. Med 9, 1356–1365 (2017).
37. Thornton, P. et al. TREM2 shedding by cleavage at the H157-S158 bond is
accelerated for the Alzheimer’s disease-associated H157Y variant. Embo Mol.
Med 9, 1366–1378 (2017).
38. Suarez-Calvet, M. et al. sTREM2 cerebrospinal fluid levels are a potential
biomarker for microglia activity in early-stage Alzheimer’s disease and
associate with neuronal injury markers. Embo Mol. Med 8, 466–476 (2016).
39. Heslegrave, A. et al. Increased cerebrospinal fluid soluble TREM2
concentration in Alzheimer’s disease. Mol. Neurodegener. 11, 3 (2016).
40. Suarez-Calvet, M. et al. Early changes in CSF sTREM2 in dominantly
inherited Alzheimer’s disease occur after amyloid deposition and neuronal
injury. Sci. Transl. Med. 8, 369ra178 (2016).
41. Piccio, L. et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer
disease and associated with mutation status. Acta Neuropathol. 131, 925–933
(2016).
42. Song, W. M. et al. Humanized TREM2 mice reveal microglia-intrinsic
and -extrinsic effects of R47H polymorphism. J. Exp. Med. 215, 745–760
(2018).
43. Zhong, L. et al. Soluble TREM2 induces inflammatory responses and enhances
microglial survival. J. Exp. Med. 214, 597–607 (2017).
44. Hansen, D. V., Hanson, J. E. & Sheng, M. Microglia in Alzheimer’s disease.
J. Cell Biol. 217, 459–472 (2018).
45. Sasaki, Y., Ohsawa, K., Kanazawa, H., Kohsaka, S. & Imai, Y. Iba1 is an actin-
cross-linking protein in macrophages/microglia. Biochem. Biophys. Res.
Commun. 286, 292–297 (2001).
46. Ahmed, Z. et al. Actin-binding proteins coronin-1a and IBA-1 are effective
microglial markers for immunohistochemistry. J. Histochem. Cytochem. 55,
687–700 (2007).
47. Elmore, M. R. et al. Colony-stimulating factor 1 receptor signaling is necessary
for microglia viability, unmasking a microglia progenitor cell in the adult
brain. Neuron 82, 380–397 (2014).
48. Spangenberg, E. E. et al. Eliminating microglia in Alzheimer’s mice prevents
neuronal loss without modulating amyloid-beta pathology. Brain 139,
1265–1281 (2016).
49. Rosario, A. M. et al. Microglia-specific targeting by novel capsid-modified
AAV6 vectors. Mol. Ther. Methods Clin. Dev. 3, 16026 (2016).
50. Youmans, K. L. et al. Amyloid-beta42 alters apolipoprotein E solubility in
brains of mice with five familial AD mutations. J. Neurosci. Methods 196,
51–59 (2011).
51. Wu, Z., Guo, Z., Gearing, M. & Chen, G. Tonic inhibition in dentate gyrus
impairs long-term potentiation and memory in an Alzheimer’s disease model.
Nat. Commun. 5, 4159 (2014).
52. Tanzi, R. E. The synaptic Abeta hypothesis of Alzheimer disease. Nat.
Neurosci. 8, 977–979 (2005).
53. Golde, T. E. The Abeta hypothesis: leading us to rationally-designed
therapeutic strategies for the treatment or prevention of Alzheimer disease.
Brain Pathol. 15, 84–87 (2005).
54. Weitz, T. M. & Town, T. Microglia in Alzheimer’s disease: it’s all about
context. Int. J. Alzheimer’s Dis. 2012, 314185 (2012).
55. Heneka, M. T., Golenbock, D. T. & Latz, E. Innate immunity in Alzheimer’s
disease. Nat. Immunol. 16, 229–236 (2015).
56. Ulrich, J. D. et al. Altered microglial response to Abeta plaques in APPPS1-21
mice heterozygous for TREM2. Mol. Neurodegener. 9, 20 (2014).
57. Lee, C. Y. D. et al. Elevated TREM2 gene dosage reprograms microglia
responsivity and ameliorates pathological phenotypes in Alzheimer’s disease
models. Neuron 97, 1032–1048 e1035 (2018).
58. Keren-Shaul, H. et al. A unique microglia type associated with restricting
development of Alzheimer’s disease. Cell 169, 1276–1290 e1217 (2017).
59. Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional
phenotype of dysfunctional microglia in neurodegenerative diseases.
Immunity 47, 566–581 e569 (2017).
60. Parkhurst, C. N. et al. Microglia promote learning-dependent synapse
formation through brain-derived neurotrophic factor. Cell 155, 1596–1609
(2013).
61. Stellwagen, D., Beattie, E. C., Seo, J. Y. & Malenka, R. C. Differential regulation
of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-
alpha. J. Neurosci. 25, 3219–3228 (2005).
62. Viviani, B. et al. Interleukin-1beta enhances NMDA receptor-mediated
intracellular calcium increase through activation of the Src family of kinases.
J. Neurosci. 23, 8692–8700 (2003).
63. Kawasaki, Y., Zhang, L., Cheng, J. K. & Ji, R. R. Cytokine mechanisms of
central sensitization: distinct and overlapping role of interleukin-1beta,
interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and
neuronal activity in the superficial spinal cord. J. Neurosci. 28, 5189–5194
(2008).
64. Liu, C. C. et al. Neuronal heparan sulfates promote amyloid pathology by
modulating brain amyloid-beta clearance and aggregation in Alzheimer’s
disease. Sci. Transl. Med. 8, 332ra344 (2016).
65. Xu, H. et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid
peptides. Nat. Med. 4, 447–451 (1998).
66. Heneka, M. T. et al. NLRP3 is activated in Alzheimer’s disease and contributes
to pathology in APP/PS1 mice. Nature 493, 674–678 (2013).
67. Wen, L. et al. VPS35 haploinsufficiency increases Alzheimer’s disease
neuropathology. J. Cell Biol. 195, 765–779 (2011).
68. Sun, H. & Neugebauer, V. mGluR1, but not mGluR5, activates feed-forward
inhibition in the medial prefrontal cortex to impair decision making.
J. Neurophysiol. 106, 960–973 (2011).
Acknowledgements
Research by the authors was supported by grants from the National Natural Science
Foundation of China 81370459, 31400914 (to X.C.), 81701079 (to L.Z.), 81373999,
81774377 (to L.W.), and 81601227 (to R.Z.), grants from the Natural Science Foundation
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09118-9 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1365 | https://doi.org/10.1038/s41467-019-09118-9 |www.nature.com/naturecommunications 15
of Guangdong Province 2016A030306005 (to X.C.), 2016A030310371 (to R.Z.), grants
from the Fundamental Research Funds for the Central Universities 20720180055
(to X.C.), grants from the Alzheimer's Association AARG-18-56635 (to X.C.), and C4C-
15-369446 (to H.X.). NIH grants RF1AG056130 (to G.B. and H.X.), R01AG035355
(to G.B.), R37AG027924 (to G.B.), and RF1AG056114 (to H.X.), grants from the Post-
doctoral Science Foundation of China 2016M600503 and 2017T100469 (to L.Z.), a grant
from the Tanz Family Funds (to H.X.), and a grant from the Natural Science Foundation
of Fujian Province 2016J05203 (to R.Z.).
Author contributions
X.C., G.B., and Li Zhong designed the project and wrote the paper; Li Zhong and Y.X.
performed all the experiments and data analyses unless otherwise indicated; T.W. and
R.H. performed mouse behavioral test; Y.X. and Y.Z. purified the sTREM2 protein; R.Z.,
Y.G., X.S., and Lin Zhu performed the electrophysiological experiment; Li Zhong, K.W.,
and D.W. performed the FACS experiment; K.W., K.C., N.W., and D.C. isolated and
cultured primary microglia; Li Zhong, Y.M., M.S., and C.L. set up and performed
sTREM2 ELISA; H.X., L.W., H.S., and D.D. reviewed the paper. All the authors read
and approved the final manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09118-9.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks Li Gan, Michela
Matteoli, and the other anonymous reviewer(s) for their contribution to the peer review
of this work.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09118-9
16 NATURE COMMUNICATIONS |         (2019) 10:1365 | https://doi.org/10.1038/s41467-019-09118-9 | www.nature.com/naturecommunications
